Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Tuesday.

According to Zacks, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sj√∂gren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. “

ANTH has been the topic of several other reports. Jefferies Group LLC reissued a “hold” rating and issued a $2.25 price objective on shares of Anthera Pharmaceuticals in a report on Monday, May 15th. ValuEngine lowered Anthera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $10.11.

Anthera Pharmaceuticals (ANTH) remained flat at $1.31 on Tuesday. The company had a trading volume of 158,421 shares. Anthera Pharmaceuticals has a 12-month low of $1.20 and a 12-month high of $28.40. The stock’s market capitalization is $13.20 million. The stock’s 50-day moving average price is $1.49 and its 200 day moving average price is $1.15.

Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.09) by $1.12. On average, equities research analysts forecast that Anthera Pharmaceuticals will post ($3.88) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This article was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/08/15/anthera-pharmaceuticals-inc-anth-stock-rating-lowered-by-zacks-investment-research.html.

Hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. raised its stake in shares of Anthera Pharmaceuticals by 1,376.1% in the first quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 335,595 shares during the last quarter. UBS Group AG raised its stake in shares of Anthera Pharmaceuticals by 9.9% in the first quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 33,901 shares during the last quarter. Finally, Sabby Management LLC raised its stake in shares of Anthera Pharmaceuticals by 1,809.7% in the first quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 1,665,655 shares during the last quarter.

Anthera Pharmaceuticals Company Profile

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Get a free copy of the Zacks research report on Anthera Pharmaceuticals (ANTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.